Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Stock Information for Savara Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Savara Inc.

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Announces New Employment Inducement Grant
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
Savara Announces New Employment Inducement Grant
Savara to Present at Two Upcoming Healthcare Conferences
Savara Introduces aPAP ClearPath(TM), a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Added to the NASDAQ Biotechnology Index

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.